TD Private Client Wealth LLC Purchases 2,449 Shares of Bristol-Myers Squibb (NYSE:BMY)

TD Private Client Wealth LLC boosted its position in Bristol-Myers Squibb (NYSE:BMY) by 3.0% during the 4th quarter, Holdings Channel reports. The fund owned 84,457 shares of the biopharmaceutical company’s stock after buying an additional 2,449 shares during the period. TD Private Client Wealth LLC’s holdings in Bristol-Myers Squibb were worth $4,777,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Kiker Wealth Management LLC bought a new position in Bristol-Myers Squibb in the fourth quarter worth approximately $344,000. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Bristol-Myers Squibb by 1.0% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 86,804 shares of the biopharmaceutical company’s stock worth $4,910,000 after purchasing an additional 829 shares during the last quarter. Douglass Winthrop Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 6.0% in the fourth quarter. Douglass Winthrop Advisors LLC now owns 39,397 shares of the biopharmaceutical company’s stock worth $2,228,000 after purchasing an additional 2,217 shares during the last quarter. Holderness Investments Co. raised its stake in shares of Bristol-Myers Squibb by 5.2% in the fourth quarter. Holderness Investments Co. now owns 42,770 shares of the biopharmaceutical company’s stock worth $2,419,000 after purchasing an additional 2,128 shares during the last quarter. Finally, Northwest & Ethical Investments L.P. raised its stake in shares of Bristol-Myers Squibb by 354.6% in the fourth quarter. Northwest & Ethical Investments L.P. now owns 73,499 shares of the biopharmaceutical company’s stock worth $4,157,000 after purchasing an additional 57,331 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on BMY shares. Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and increased their price objective for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. Citigroup increased their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Bank of America reaffirmed a “neutral” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Wells Fargo & Company increased their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Friday, February 7th. Finally, Truist Financial increased their price target on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $57.86.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,823 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now owns 63,932 shares of the company’s stock, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Stock Performance

NYSE:BMY opened at $61.06 on Friday. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The business has a fifty day simple moving average of $58.17 and a two-hundred day simple moving average of $55.89. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The company has a market capitalization of $123.92 billion, a P/E ratio of -13.82, a P/E/G ratio of 2.07 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. On average, analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.06%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb’s payout ratio is currently -56.11%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.